Company intelligence / Profile preview

REMA

Ownership: Private
Development stage: Other

Overview

REMA has developed a patented biotechnology platform that uses beneficial microorganisms and microalgae to remediate contaminated soils, stabilize tailings, capture CO₂, transform pollutants like heavy metals/nitrates, promote biodiversity, and restore degraded ecosystems. The technology has been validated outside the lab at scale. The US branch also pursues public health-focused biotech innovation targeting infectious diseases/chronic conditions. Strategic partnerships are expanding global reach.

Modalities: Microbial therapyMicroalgae-based therapy
Industry: Biotech

Partnerships

Cemvita

Beyond the preview

Go deeper on REMA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REMA.

Explore the full profile